Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
APD916 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| APD916 | DRUG | - |
APD916 is an investigational small molecule being developed for the treatment of narcolepsy with or without cataplexy. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
APD916 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug.
APD916 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved for any use. The Phase 1 trial has been completed.
APD916 has one completed Phase 1 clinical trial, identified as NCT01093508, titled "Single-dose Safety Study of APD916 in Healthy Volunteers." The trial enrolled 72 participants and was an uncontrolled, open-label study.
APD916 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for narcolepsy with or without cataplexy. The completed Phase 1 trial was a single-dose safety study in healthy volunteers.